...–2% of non-small-cell lung cancer (NSCLC) cases. Although crizotinib, a tyrosine kinase inhibitor (TKI) against ALK/ROS1, is known to be effective against ROS1-fusion-positive NSCLC, such cases sometimes progress with brain metastases. The most frequently reported crizotinib-resistance mutation...

..., with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid...

...Sachi Okawa; Takuo Shibayama; Atsushi Shimonishi; Jun Nishimura; Taichi Ozeki; Kenji Takada; Hiroe Kayatani; Daisuke Minami; Ken Sato; Keiichi Fujiwara; Toshiro Yonei; Toshio Sato; Manabu Suno Although crizotinib shows marked antitumor activity in anaplastic lymphoma kinase (ALK) rearrangement...

...Adeline Rosoux; Fabrice Duplaquet; Sebahat Ocak Background: Crizotinib is an approved tyrosine kinase inhibitor in the treatment of advanced-stage non-small-cell lung cancer patients with anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement. Renal dysfunction after crizotinib...

... of cisplatin + pemetrexed and crizotinib. The present case indicates that alopecia should be taken into consideration as toxicity during alectinib treatment, which could adversely affect the psychological and emotional condition and quality of life even in patients treated with specific molecular targeted...

...Jun Osugi; Yuki Owada; Takumi Yamaura; Satoshi Muto; Naoyuki Okabe; Yuki Matsumura; Mitsunori Higuchi; Hiroyuki Suzuki; Mitsukazu Gotoh Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia...

...Laura Deiana; Salvatore Grisanti; Vittorio Ferrari; Andrea Tironi; Giulia Brugnoli; Laura Ferrari; Giordano Bozzola; Alfredo Berruti Crizotinib is an efficacious and well-tolerated drug in the management of ALK-positive lung cancer. Crizotinib treatment, however, is rarely complicated...

...Yoshihiko Sakata; Kodai Kawamura; Kazuya Ichikado; Masakazu Yoshioka Orbital metastasis of lung cancer is rare. It often causes visual disorder. To date, there are only a few case reports. Crizotinib is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that leads to responses in most...

...Nobuhiro Asai; Toyoharu Yokoi; Etsuro Yamaguchi; Akihito Kubo Crizotinib, a first-line anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor, has shown promising results for the treatment of locally advanced and metastatic lung cancer presenting the ALK rearrangement. On the other hand...

... was inconclusive in determining the site of origin. Although the lung biopsy sample was insufficient for molecular testing, hybrid capture-based comprehensive genomic profiling (FoundationOne) identified an EML4-ALK rearrangement in the RUE lesion. Crizotinib treatment resulted in a major response in both the RUE...

... greater efficacy and less toxicity but is most likely to be effective when pairing a tumor harboring a sensitizing genomic alteration with an agent directed at the altered gene product. We report a patient with a CUP harboring a MET amplification with a complete metabolic response to crizotinib despite...

.... Molecular testing revealed that his tumor had an echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangement. Therefore, he was treated with crizotinib when his disease recurred. He achieved a partial response, which persisted for 10 months until progressive disease...